Last reviewed · How we verify
VL#FIA3-30
VL#FIA3-30 is a Small molecule drug developed by VasoLead (2012) Ltd.. It is currently in Phase 1 development. Also known as: Transdermal application.
At a glance
| Generic name | VL#FIA3-30 |
|---|---|
| Also known as | Transdermal application |
| Sponsor | VasoLead (2012) Ltd. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- VL#FIA3-30 CI brief — competitive landscape report
- VL#FIA3-30 updates RSS · CI watch RSS
- VasoLead (2012) Ltd. portfolio CI
Frequently asked questions about VL#FIA3-30
What is VL#FIA3-30?
VL#FIA3-30 is a Small molecule drug developed by VasoLead (2012) Ltd..
Who makes VL#FIA3-30?
VL#FIA3-30 is developed by VasoLead (2012) Ltd. (see full VasoLead (2012) Ltd. pipeline at /company/vasolead-2012-ltd).
Is VL#FIA3-30 also known as anything else?
VL#FIA3-30 is also known as Transdermal application.
What development phase is VL#FIA3-30 in?
VL#FIA3-30 is in Phase 1.
Related
- Manufacturer: VasoLead (2012) Ltd. — full pipeline
- Also known as: Transdermal application
- Compare: VL#FIA3-30 vs similar drugs
- Pricing: VL#FIA3-30 cost, discount & access